← Back to all trials
Enrolling By Invitation
NCT06167642
Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab
Conditions: Multiple Sclerosis, Tomography, Optical Coherence, Retinal Degeneration, Visual Acuity
Sex: All
Ages: 18 Years – 70 Years
Healthy volunteers: No
Enrollment: 75
Sponsor: Johns Hopkins University
Location: Johns Hopkins Baltimore Maryland
Summary
This study aims to assess whether, and the degree to which, ofatumumab modulates or reduces rates of retinal atrophy in people with relapsing-remitting MS (RMS), according to baseline serum neurofilament light chain (sNfL) levels.
Eligibility Criteria
Inclusion Criteria:
1. Between 18 - 70 years of age
2. Have RMS as confirmed by the treating neurologist based on the 2017 revised McDonald criteria
AND Either
* be due to commence ofatumumab within 60 days of baseline OCT/VA/phlebotomy or
* be existing patients attending the center and already receiving ofatumumab, be eligible for inclusion, and already undergoing all of the proposed study procedures.
3. Willing to sign informed consent
4. Willing to undergo phlebotomy
Exclusion Criteria:
* Uncontrolled Diabetes
* Uncontrolled Hypertension
* Glaucoma
* Refractive errors of +/- 6 diopters
* Other neurologic or ophthalmologic disorders
Source: ClinicalTrials.gov (NCT06167642). StuddyBuddy aggregates publicly available trial information.
